<DOC>
	<DOCNO>NCT01235351</DOCNO>
	<brief_summary>To determine whether high compare low maintenance dos clopidogrel adequately improve degree platelet inhibition carrier reduced-function CYP2C19 allele .</brief_summary>
	<brief_title>Escalating Clopidogrel Involving Genetic Strategy - Thrombolysis In Myocardial Infarction 56</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Inclusion Criteria ( major ) : 1 . Between 18 75 year age , inclusive . 2 . Have indication use clopidogrel define either spontaneous MI [ hospitalize final diagnosis MI , exclude periprocedural definite secondary MI ( e.g. , due anemia hypertensive emergency ) ] PCI within past 6 month . 3 . Clinically stable least 4 week follow MI PCI . Exclusion Criteria ( major ) : 1 . Conditions alter platelet function . 2 . Conditions increase bleed risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Genetics</keyword>
	<keyword>Platelet Function</keyword>
</DOC>